Reevaluation of the cancer potency factor of toxaphene: Recommendations from a peer review panel

Jay I. Goodman, David J. Brusick, William M. Busey, Samuel Monroe Cohen, James C. Lamb, Thomas B. Starr

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

This reevaluation of the current U.S. EPA cancer potency factor for toxaphene is based upon a review of toxaphene carcinogenesis bioassays in mice conducted by Litton Bionetics (unpublished report, 1978) and the National Cancer Institute (NCI) (Technical Report Series No. 37, conducted by Gulf South Research Institute, 1979). The mechanistic data available for toxaphene, including consideration of the potential of the compound to induce genotoxicity, was examined with an emphasis on whether this information supports a change in the cancer potency factor. If a quantitative dose- response assessment for toxaphene is to be performed, the data from both the NCI and Litton cancer bioassays should be used. Additionally, liver tumor results from female mice, rather than male mice, should be used for estimating potential human cancer risk because the background rate of liver tumors in females is lower and less variable than that exhibited by males. An ED10 was estimated as the point of departure. The mechanistic data were not sufficient to fully support a margin of exposure approach. Therefore, we believe that applying a linear extrapolation from the ED10 to the origin is an appropriate means to estimate risk at low doses. This is a highly conservative approach and, when it is applied, we conclude that the current EPA cancer potency factor should be reduced from 1.1 (mg/kg/day)-1 to 0.1 (mg/kg/day)-1.

Original languageEnglish (US)
Pages (from-to)3-16
Number of pages14
JournalToxicological Sciences
Volume55
Issue number1
StatePublished - May 22 2000

Fingerprint

Toxaphene
Peer Review
Bioassay
Liver
Tumors
Neoplasms
National Cancer Institute (U.S.)
Biological Assay
Extrapolation
Carcinogenesis

Keywords

  • Cancer potency factor
  • Margin of exposure
  • Pathology working group (PWG)
  • Toxaphene

ASJC Scopus subject areas

  • Toxicology

Cite this

Goodman, J. I., Brusick, D. J., Busey, W. M., Cohen, S. M., Lamb, J. C., & Starr, T. B. (2000). Reevaluation of the cancer potency factor of toxaphene: Recommendations from a peer review panel. Toxicological Sciences, 55(1), 3-16.

Reevaluation of the cancer potency factor of toxaphene : Recommendations from a peer review panel. / Goodman, Jay I.; Brusick, David J.; Busey, William M.; Cohen, Samuel Monroe; Lamb, James C.; Starr, Thomas B.

In: Toxicological Sciences, Vol. 55, No. 1, 22.05.2000, p. 3-16.

Research output: Contribution to journalReview article

Goodman, JI, Brusick, DJ, Busey, WM, Cohen, SM, Lamb, JC & Starr, TB 2000, 'Reevaluation of the cancer potency factor of toxaphene: Recommendations from a peer review panel', Toxicological Sciences, vol. 55, no. 1, pp. 3-16.
Goodman, Jay I. ; Brusick, David J. ; Busey, William M. ; Cohen, Samuel Monroe ; Lamb, James C. ; Starr, Thomas B. / Reevaluation of the cancer potency factor of toxaphene : Recommendations from a peer review panel. In: Toxicological Sciences. 2000 ; Vol. 55, No. 1. pp. 3-16.
@article{33664bc4147e4588b5c1ce9ba317a6a1,
title = "Reevaluation of the cancer potency factor of toxaphene: Recommendations from a peer review panel",
abstract = "This reevaluation of the current U.S. EPA cancer potency factor for toxaphene is based upon a review of toxaphene carcinogenesis bioassays in mice conducted by Litton Bionetics (unpublished report, 1978) and the National Cancer Institute (NCI) (Technical Report Series No. 37, conducted by Gulf South Research Institute, 1979). The mechanistic data available for toxaphene, including consideration of the potential of the compound to induce genotoxicity, was examined with an emphasis on whether this information supports a change in the cancer potency factor. If a quantitative dose- response assessment for toxaphene is to be performed, the data from both the NCI and Litton cancer bioassays should be used. Additionally, liver tumor results from female mice, rather than male mice, should be used for estimating potential human cancer risk because the background rate of liver tumors in females is lower and less variable than that exhibited by males. An ED10 was estimated as the point of departure. The mechanistic data were not sufficient to fully support a margin of exposure approach. Therefore, we believe that applying a linear extrapolation from the ED10 to the origin is an appropriate means to estimate risk at low doses. This is a highly conservative approach and, when it is applied, we conclude that the current EPA cancer potency factor should be reduced from 1.1 (mg/kg/day)-1 to 0.1 (mg/kg/day)-1.",
keywords = "Cancer potency factor, Margin of exposure, Pathology working group (PWG), Toxaphene",
author = "Goodman, {Jay I.} and Brusick, {David J.} and Busey, {William M.} and Cohen, {Samuel Monroe} and Lamb, {James C.} and Starr, {Thomas B.}",
year = "2000",
month = "5",
day = "22",
language = "English (US)",
volume = "55",
pages = "3--16",
journal = "Toxicological Sciences",
issn = "1096-6080",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Reevaluation of the cancer potency factor of toxaphene

T2 - Recommendations from a peer review panel

AU - Goodman, Jay I.

AU - Brusick, David J.

AU - Busey, William M.

AU - Cohen, Samuel Monroe

AU - Lamb, James C.

AU - Starr, Thomas B.

PY - 2000/5/22

Y1 - 2000/5/22

N2 - This reevaluation of the current U.S. EPA cancer potency factor for toxaphene is based upon a review of toxaphene carcinogenesis bioassays in mice conducted by Litton Bionetics (unpublished report, 1978) and the National Cancer Institute (NCI) (Technical Report Series No. 37, conducted by Gulf South Research Institute, 1979). The mechanistic data available for toxaphene, including consideration of the potential of the compound to induce genotoxicity, was examined with an emphasis on whether this information supports a change in the cancer potency factor. If a quantitative dose- response assessment for toxaphene is to be performed, the data from both the NCI and Litton cancer bioassays should be used. Additionally, liver tumor results from female mice, rather than male mice, should be used for estimating potential human cancer risk because the background rate of liver tumors in females is lower and less variable than that exhibited by males. An ED10 was estimated as the point of departure. The mechanistic data were not sufficient to fully support a margin of exposure approach. Therefore, we believe that applying a linear extrapolation from the ED10 to the origin is an appropriate means to estimate risk at low doses. This is a highly conservative approach and, when it is applied, we conclude that the current EPA cancer potency factor should be reduced from 1.1 (mg/kg/day)-1 to 0.1 (mg/kg/day)-1.

AB - This reevaluation of the current U.S. EPA cancer potency factor for toxaphene is based upon a review of toxaphene carcinogenesis bioassays in mice conducted by Litton Bionetics (unpublished report, 1978) and the National Cancer Institute (NCI) (Technical Report Series No. 37, conducted by Gulf South Research Institute, 1979). The mechanistic data available for toxaphene, including consideration of the potential of the compound to induce genotoxicity, was examined with an emphasis on whether this information supports a change in the cancer potency factor. If a quantitative dose- response assessment for toxaphene is to be performed, the data from both the NCI and Litton cancer bioassays should be used. Additionally, liver tumor results from female mice, rather than male mice, should be used for estimating potential human cancer risk because the background rate of liver tumors in females is lower and less variable than that exhibited by males. An ED10 was estimated as the point of departure. The mechanistic data were not sufficient to fully support a margin of exposure approach. Therefore, we believe that applying a linear extrapolation from the ED10 to the origin is an appropriate means to estimate risk at low doses. This is a highly conservative approach and, when it is applied, we conclude that the current EPA cancer potency factor should be reduced from 1.1 (mg/kg/day)-1 to 0.1 (mg/kg/day)-1.

KW - Cancer potency factor

KW - Margin of exposure

KW - Pathology working group (PWG)

KW - Toxaphene

UR - http://www.scopus.com/inward/record.url?scp=0034104621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034104621&partnerID=8YFLogxK

M3 - Review article

C2 - 10788554

AN - SCOPUS:0034104621

VL - 55

SP - 3

EP - 16

JO - Toxicological Sciences

JF - Toxicological Sciences

SN - 1096-6080

IS - 1

ER -